Eddie A. Young
AstraZeneca has announced that its lung-cancer drug Enhertu has received a recommendation for approval in the European Union following positive test results. This is a significant milestone for the anglo-swedish pharmaceutical company.
Enhertu showed promising results in the tests conducted, with an objective response rate of 49.0% and a median duration of response of 16.8 months. Additionally, the tests indicated a disease control rate of 93.1%.
The drug has been recommended as a monotherapy for the treatment of adult patients with advanced non-small-cell lung cancer who have tumors with an activating HER2 mutation. This particular form of lung cancer is aggressive and commonly affects younger patients. Unfortunately, it has a poor prognosis, with limited approved treatment options available.
If approved, Enhertu will be the first targeted treatment option available for patients suffering from this specific type of lung cancer. The recognition of this unmet need in the European Union marks a significant step forward in providing better treatment options for these patients.
Enhertu is being jointly developed and commercialized in collaboration with Japan's Daiichi Sankyo.
Berkshire Hathaway, led by Warren Buffett, has made a secret billion-dollar stock investment, sparking speculation. The...
WeWork, once a major office tenant, faced financial struggles and eventually filed for bankruptcy. Explore the rise and...
Goldman Sachs is optimistic about investors increasing their exposure to equities as long as the economy remains on trac...
Bitcoin's recent decline below key technical levels may indicate further drops in the stock market, highlighting its rol...
Leave A Reply
Your email address will not be published. Required fields are marked *